Two Centers, One Mission

The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will 1) design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD), and 2) initiate early stage drug discovery campaigns against the enabled targets. Central to this initiative is the open-access, rapid dissemination of data, methods, and computational and experimental tools generated by the Centers to all qualified researchers for their use in advancing AD drug discovery and AD disease biology.

TREAT-AD Leadership Team:

Allan Levey, Emory University

Lara Mangravite, Sage Bionetworks

Aled Edwards, SGC and University of Toronto

Alan Palkowitz, Indiana University School of Medicine

Bruce Lamb, Indiana University School of Medicine

Lorenzo Refolo, NIA/NIH

Suzana Petanceska, NIA/NIH

External Advisory Board:

Kelly Bales, Voyager Therapeutics Inc.

David Collier, Eli Lilly

Gabriela Chiosis, Sloan Kettering Institute

Rebecca Edelmayer, Alzheimer’s Association

Nilufer Ertekin-Taner, Mayo Clinic

Mark Gurney, Tetra Therapeutics

David Holtzman, Washington University School of Medicine, St. Louis

Philip De Jager, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University

Kalpana Merchant, Adjunct Professor of Neurology at Northwestern University Feinberg School of Medicine

Eric Siemers, Siemers Integration LLC

Reisa Sperling, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School

Linda Van Eldik, Sanders-Brown Center on Aging, University of Kentucky